Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Image-Guided Focused Ultrasound Gains Ground As Noninvasive Therapeutic Tool

Executive Summary

Research into the use of image-guided focused ultrasound (IgFUS) as a noninvasive therapeutic modality is starting to achieve the kind of critical mass - in clinical outcomes data and R&D investment - necessary to win the interest and support of clinicians, payors, and regulators. Although there is still a good distance to travel before the technology achieves a routine place in the therapeutic toolkit, IgFUS is clearly an up-and-coming field in the medical device arena, and many believe it has the potential to revolutionize the treatment paradigm in a number of clinical areas.

You may also be interested in...

New Product Briefs: Medtronic CRT-D; Syncardia Valve; Lombard AAA Graft

Medtronic is set for the U.S. launch of the Viva Quad XT and Viva Quad S cardiac resynchronization devices. Syncardia earns FDA approval for a new propriety valve set for its total artificial heart. Lombard earns Japanese approval for its AAA graft. Philips announces a unique case in Canada.

Advancing Ablative Tumor Therapies Into Primary Treatments

For many cancers, there is a need for a third option between the two current choices of radical tissue destruction and watchful waiting. New cancer ablation devices in development have the potential to fill that gap. Ablative tumor therapies can play a role in eradication of early-stage and localized tumors, as salvage therapies in patients who've failed other therapies, and for patients whose health precludes surgery or further radiation. Ablation has many advantages. It's a cost-effective and minimally invasive alternative to robotic surgery or radiation devices, and may lead to fewer side effects and complications than current primary tumor treatments. But proving that ablation can save lives compared to more radical forms of therapy requires clinical evidence from multiyear outcome trials that few smaller companies are willing to invest in. There's little evidence to date that venture investors will see returns. But the race is on among companies hoping to become the first device approved for low-risk, localized prostate cancer, a potentially game-changing event.

Seeking New Options for Prostate Cancer

Recent reports questioning the benefits of early prostate cancer diagnosis and treatment have raised an industry-wide debate that has been fueled by the limitations of prostate-specific antigen tests, currently the standard of care for early prostate cancer detection. While the industry searches to improve the use of PSA tests, urologists are asking, "are we over treating our patients?" That question was repeatedly voiced in a number of forums at the American Urological Association's 2010 Annual Meeting. As for a definitive answer to the question, it is a somewhat difficult task to get individual physicians to admit they are personally over treating patients; however, there is definitely a consensus-and a concern-that more patients than necessary are receiving treatments that put them at risk of serious side effects.

Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts